Provention Bio, Inc. (PRVB) Income Statement Analysis

See more : Charm Engineering Co.,Ltd. (009310.KS) Income Statement Analysis – Financial Results

Complete financial analysis of Provention Bio, Inc. (PRVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Provention Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Chevron Corporation (CVX) Income Statement Analysis – Financial Results
Barwa Real Estate Company Q.P.S.C. (BRES.QA) Income Statement Analysis – Financial Results
DigitalBridge Group, Inc. (6CL.F) Income Statement Analysis – Financial Results
Nippon Steel Corporation (NISTF) Income Statement Analysis – Financial Results
Osstem Implant Co., Ltd. (048260.KQ) Income Statement Analysis – Financial Results

Provention Bio, Inc. (PRVB)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.proventionbio.com

About Provention Bio, Inc.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Metric	2022	2021	2020	2019	2018	2017
Revenue	12.90M	1.40M	0.00	0.00	0.00	0.00
Cost of Revenue	512.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	12.38M	1.40M	0.00	0.00	0.00	0.00
Gross Profit Ratio	96.03%	100.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	75.80M	69.63M	66.36M	36.36M	22.65M	7.68M
General & Administrative	64.11M	47.35M	33.33M	8.01M	4.17M	1.46M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	64.11M	47.35M	33.33M	8.01M	4.17M	1.46M
Other Expenses	627.00K	0.00	0.00	0.00	0.00	0.00
Operating Expenses	140.54M	116.97M	99.69M	44.37M	26.81M	9.14M
Cost & Expenses	141.06M	116.97M	99.69M	44.37M	26.81M	9.14M
Interest Income	2.24M	146.00K	583.00K	1.09M	669.00K	131.50K
Interest Expense	1.04M	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.47M	387.00K	33.00K	-16.00K	149.00K	6.50K
EBITDA	-124.69M	-115.58M	-99.69M	-44.37M	-26.67M	-9.13M
EBITDA Ratio	-966.98%	-8,285.16%	0.00%	0.00%	0.00%	0.00%
Operating Income	-128.16M	-115.58M	-99.69M	-44.37M	-26.81M	-9.14M
Operating Income Ratio	-993.88%	-8,285.16%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	1.20M	146.00K	583.00K	1.09M	149.00K	6.50K
Income Before Tax	-126.96M	-115.43M	-99.10M	-43.29M	-26.67M	-9.13M
Income Before Tax Ratio	-984.54%	-8,274.70%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-13.39M	-1.00M	-523.00K	-1.09M	-187.00K	-131.50K
Net Income	-113.57M	-114.43M	-98.58M	-42.20M	-26.48M	-9.13M
Net Income Ratio	-880.69%	-8,203.01%	0.00%	0.00%	0.00%	0.00%
EPS	-1.52	-1.81	-1.88	-1.04	-1.18	-0.27
EPS Diluted	-1.52	-1.81	-1.88	-1.04	-1.18	-0.27
Weighted Avg Shares Out	74.72M	63.10M	52.46M	40.75M	22.44M	33.88M
Weighted Avg Shares Out (Dil)	74.72M	63.10M	52.46M	40.75M	22.44M	33.88M

2 Beaten-Down Stocks That Might Be too Cheap to Ignore

February 22, 2023fool.com

There is an argument for hitting the buy button, but it's important to consider the potential risks too.

Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?

February 13, 2023zacks.com

Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US

February 13, 2023prnewswire.com

Companies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes RED BANK, N.J. , Feb. 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and...

Here's Why 'Trend' Investors Would Love Betting on Provention Bio, Inc. (PRVB)

February 8, 2023zacks.com

Provention Bio, Inc. (PRVB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Provention Bio: Ability To Expand T1D Market Presence With Second Half 2023 Data

February 7, 2023seekingalpha.com

Received FDA approval of TZIELD for Stage 2 Type 1 Diabetes patients in November of 2022. Potential to increase market potential of TZIELD with ongoing phase 3 PROTECT study, which is being used for stage 3 newly diagnosed T1D patients....

Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®

February 2, 2023prnewswire.com

RED BANK, N.J. , Feb. 2, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the close of the $40 million second tranche under the previously announced term...